https://www.ncbi.nlm.nih.gov/pubmed/?term=30097845 Hepatitis C
Indian J Pediatr. 2019 Feb;86(2):148-153. doi: 10.1007/s12098-018-2752-7. Epub 2018 Aug 10.
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Nagral A1,2,3, Jhaveri A4, Sawant S5, Parikh NS4, Nagral N6, Merchant R7, Gandhi M8,9,10.
Author information

Abstract

OBJECTIVES:
To assess the efficacy and safety of sofosbuvir based generic Direct Acting Antivirals (DAAs) in treatment of Hepatitis C virus (HCV) in adolescents with thalassemia major (TM).

METHODS:
In this prospective single-arm study, 18 TM adolescents with Chronic Hepatitis C received sofosbuvir based generic DAAs. Patients with genotype 1 and genotype 3 received ledipasvir and daclatasvir respectively. Two cirrhotic patients with genotype 3 also received ribavirin.

RESULTS:
The mean age of patients was 15.1 y, of which 12 had genotype 1, 5 had genotype 3 and 1 had an undetermined genotype. Six patients had cirrhosis and 1 was treatment experienced. Sixteen of 18 patients (89%; 95% confidence interval 74 to 100%) achieved sustained virological response at 3 mo post completion of treatment with DAAs. There was a significant reduction in alanine aminotransferase levels (p < 0.001), HCV RNA load (p < 0.001) and ferritin levels (p < 0.026) at 3 mo post completion of treatment. There were no major adverse events associated with the use of DAAs.

CONCLUSIONS:
Generic DAAs are effective and safe in TM adolescents with HCV.